Novo Nordisk and GoodRx announced a partnership to offer pricing discounts for patients who pay out-of-pocket for the new oral version of Ozempic (semaglutide). The deal aims to make the pill form of this weight-loss and diabetes drug more affordable for uninsured or underinsured customers.

• •Novo Nordisk and GoodRx partnered on self-pay pricing for oral Ozempic (semaglutide).
• •Deal targets uninsured or underinsured patients paying out-of-pocket.

GoodRx, a pharmacy discount platform, is now helping patients access oral semaglutide (the pill form of Ozempic). The move makes it easier for people to get this weight-loss and diabetes drug through a different delivery method than the popular injection.

• •GoodRx is enabling patient access to oral semaglutide, the pill form of Ozempic
• •Move expands availability beyond the injectable version

GoodRx, a prescription discount service, now offers Rybelsus (the oral tablet form of semaglutide, the active ingredient in Ozempic) to patients with type 2 diabetes. The move expands GoodRx's existing GLP-1 product lineup to include an oral option alongside injectable versions.

• •GoodRx now offers Rybelsus, the oral tablet form of semaglutide, for type 2 diabetes patients
• •Move expands GoodRx's existing GLP-1 lineup to include an oral option alongside injectables